Download oncology development pipeline

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript 
ONCOLOGY DEVELOPMENT PIPELINE
PROGRAM
DESCRIPTION
DEVELOPMENT RIGHTS
DISEASE(S) UNDER INVESTIGATION
CD30 Antibody Drug Conjugate
Global†‡
Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma,
Mature T-Cell Lymphoma
VECTIBIX®
Anti-EGFR Antibody
Japan Only
Colorectal Cancer
LEUPLIN®
LH-RH Agonist
Japan Only
Prostate Cancer, Breast Cancer, new formulation
NINLARO®
Proteasome Inhibitor
Global
Multiple Myeloma, Amyloidosis
Lymphoma
ALISERTIB
Aurora A Kinase Inhibitor
Global
Small Cell Lung Cancer
TAK-228
TORC1/TORC2 Inhibitor
Global
Metastatic Breast Cancer, Renal Cell Carcinoma, Endometrial Cancer
PEVONEDISTAT
Nedd8-Activating Enzyme Inhibitor
Global
Myelodysplastic Syndrome
Solid Tumors
TAK-659
SYK/FLT-3 Kinase Inhibitor
Global
Acute Myelogenous Leukemia, Lymphoma
Solid Tumors
TAK-117
PI3K Alpha Inhibitor
Global
Non-Small Cell Lung Cancer
Gastric Cancer
TAK-580
Pan-Raf Kinase Inhibitor
Global
Solid Tumors
TAK-243
UAE Inhibitor
Global
Solid Tumors
TAK-931
CDC7 Inhibitor
Global
Solid Tumors
ADCETRIS®
(brentuximab vedotin)
†‡
(panitumumab)†
(Leuprorelin acetate)
(ixazomib)
‡ADCETRIS® is co-developed by Takeda and Seattle Genetics, Inc.
†In-Licensed
All registered trademarks are the sole property of their respective owners.
Last updated 08/17/2016
PHASE 1
PHASE 2
PHASE 3
Related documents